Full-Length Dominant-Negative Survivin for Cancer Immunotherapy

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6523-6533

  Pisarev, Vladimir ^a   Yu, Bin ^b   Salup, Raoul ^b   Sherman, Simon ^a   Altieri, Dario C ^c   Gabrilovich, Dmitry I ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CD34 ANTIGEN; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CELL STRAIN K 562; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOMINANT GENE; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOVIRIDAE; ADULT; AGED; ANTIGENS, CD34; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENES, DOMINANT; HEMATOPOIETIC STEM CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; PROSTATIC NEOPLASMS; STEM CELLS;

EID: 0348019096     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer, 3: 46-54, 2003.
2. Zhao, J., Tenev, T., Martins, L. M., Downward, J., and Lemoine, N. R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci., 113: 4363-4371, 2000.
3. Miller, M., Smith, D., Windsor, A., and Kessling, A. Survivin gene expression and prognosis in recurrent colorectal cancer. Gut, 48: 137-138, 2001.
4. Kawasaki, H., Toyoda, M., Shinohara, H., Okuda, J., Watanabe, I., Yamamoto, T., Tanaka, K., Tenjo, T., and Tanigawa, N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer (Phila.), 91: 2026-2032, 2001.
5. Kato, J., Kuwabara, Y., Mitani, M., Shinoda, N., Sato, A., Toyama, T., Mitsui, A., Nishiwaki, T., Moriyama, S., Kudo, J., and Fujii, Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer, 95: 92-95, 2001.
6. Sarela, A. I., Verbeke, C. S., Ramsdale, J., Davies, C. L., Markham, A. F., and Guillou, P. J. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br. J. Cancer, 86: 886-892, 2002.
7. Williams, N. S., Gaynor, R. B., Scoggin, S., Verma, U., Gokaslan, T., Simmang, C., Fleming, J., Tavana, D., Frenkel, E., and Becerra, C. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin. Cancer Res., 9: 931-946, 2003.
8. Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., and Tanigawa, N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res., 6: 127-134, 2000.
9. Smith, S. D., Wheeler, M. A., Plescia, J., Colberg, J. W., Weiss, R. M., and Altieri, D. C. Urine detection of survivin and diagnosis of bladder cancer. J. Am. Med. Assoc., 285: 324-328, 2001.
10. Ito, T., Shiraki, K., Sugimoto, K., Yamanaka, T., Fujikawa, K., Ito, M., Takase, K., Moriyama, M., Kawano, H., Hayashida, M., Nakano, T., and Suzuki, A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology, 31: 1080-1085, 2000.
11. Grossman, D., McNiff, J. M., Li, F., and Altieri, D. C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Investig. Dermatol., 113: 1076-1081, 1999.
12. Moriai, R., Asanuma, K., Kobayashi, D., Yajima, T., Yagihashi, A., Yamada, M., and Watanabe, N. Quantitative analysis of the antiapoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res., 21: 595-600, 2001.
13. Sarela, A. I., Scott, N., Ramsdale, J., Markham, A. F., and Guillou, P. J. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol., 8: 305-310, 2001.
14. Zaffaroni, N., and Daidone, M. G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat., 5: 65-72, 2002.
15. Ambrosini, G., Adida, C., and Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3: 917-921, 1997.
16. Fukuda, S., and Pelus, L. M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic grwoth factors: implication of survivin expression in normal hematopoiesis. Blood, 98: 2091-2100, 2001.
17. Zhang, T., Otevrel, T., Gao, Z., Gao, Z., Ehrlich, S. M., Fields, J. Z., and Boman, B. M. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res., 61: 8664-8667, 2001.
18. Mesri, M., Morales-Ruiz, M., Ackermann, E. J., Bennett, C. F., Pober, J. S., Sessa, W. C., and Altieri, D. C. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol., 158: 1757-1765, 2001.
19. Rohayem, J., Diestelkoetter, P., Weigle, B., Oehmichen, A., Schmitz, M., Mehlhorn, J., Conrad, K., and Rieber, E. P. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res., 60: 1815-1817, 2000.
20. Schmitz, M., Diestelkoetter, P., Weigle, B., Schmachtenberg, F., Stevanovic, S., Ockert, D., Rammensee, H. G., and Rieber, E. P. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res., 60: 4845-4849, 2000.
21. Andersen, M. H., Pedersen, L. O., Becker, J. C., and Straten, P. T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res., 61: 869-872, 2001.
22. Casati, C., Dalerba, P., Rivoltini, L., Gallino, G., Deho, P., Rini, F., Belli, F., Mezzanzanica, D., Costa, A., Andreola, S., Leo, E., Parmiani, G., and Castelli, C. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res., 63: 4507-4515, 2003.
23. Meek, D. W. Post-translational modification of p53. Semin. Cancer Biol., 5: 203-210, 1994.
24. Daniels, M. A., Hogquist, K. A., and Jameson, S. C. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat. Immunol., 3: 903-910, 2002.
25. Pavao, M., and Traish, A. M. Estrogen receptor antibodies: specificity and utility in detection, localization and analyses of estrogen receptor α and β Steroids, 66: 1-16, 2001.
26. Thomson, S. A., Khanna, R., Gardner, J., Burrows, S., Coupar, B., Moss, D. J., and Suhrbier, A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA, 92: 5845-5849, 1995.
27. Wan, Y., Bramson, J., Carter, R., Graham, F., and Gauldie, J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther., 8: 1355-1363, 1997.
28. Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S., and Bevan, M. J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol., 158: 3270-3276, 1997.
29. Song, W., Kong, H. L., Carpenter, H., Torii, H., Granstein, R., Rafii, S., Moore, M. A. S., and Crystal, R. G. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med., 186: 1247-1256, 1997.
30. Wan, Y. H., Emtage, P., Zhu, Q., Foley, R., Pilon, A., Roberts, B., and Gauldie, J. Enhanced immune response to the melanoma antigen gp1OO using recombinant adenovirus-transduced dendritic cells. Cell. Immunol., 198: 131-138, 1999.
31. Kaplan, J. M., Yu, Q. E., Piraino, S. T., Pennington, S. E., Shankara, S., Woodworth, L. A., and Roberts, B. L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol., 163: 699-707, 1999.
32. Nikitina, E. Y., Clark, J. I., van Beynen, J., Chada, S., Virmani, A. K., Carbone, D. P., and Gabrilovich, D. I. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res., 7: 127-135, 2001.
33. Blasczyk, R., Hahn, U., Wehling, J., Huhn, D., and Salama, A. Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis. Tissue Antigens, 46: 86-95, 1995.
34. Mesri, M., Wall, N. R., Li, J., Kim, R. W., and Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. Clin. Investig., 108: 981-990, 2001.
35. Kuttler, C., Nussbaum, A. K., Dick, T. P., Rammensee, H-G., Schild, H., and Hadeler, K. An algorithm for the prediction of proteasomal cleavages. J. Mol. Biol., 298: 417-429, 2000.
36. Nussbaum, A. K., Kuttler, C., Hadeler, K. P., Rammensee, H-G., and Schild, H. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics, 53: 87-94, 2001.
37. BMI Biomedical Informatics-Heidelberg. http://syfpeithi.bmi-heidelberg.com.
38. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
39. Almand, B., Clark, J. I., Nikitina, E., English, N. R., Knight, S. C., Carbone, D. P., and Gabrilovich, D. I. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J. Immunol., 166: 678-689, 2001.
40. Schmidt, S. M., Schag, K., Muller, M. R., Weck, M. M., Appel, S., Kanz, L., Grunebach, F., and Brossart, P. Survivin is a shared tumor associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T-cells. Blood, 102: 571-576, 2003.
41. Nikitina, E. Y., Chada, S., Muro-Cacho, C., Fang, B., Zhang, R., Roth, J. A., and Gabrilovich, D. I. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther., 9: 345-352, 2002.
42. Okada, N., Masunaga, Y., Okada, Y., Iiyama, S., Mori, N., Tsuda, T., Matsubara, A., Mizuguchi, H., Hayakawa, T., Fujita, T., and Yamamoto, A. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther., 10: 421-431, 2003.
43. Herrera, O. B., Brett, S., and Lechler, R. I. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Vaccine, 21: 231-242, 2002.